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Efficient long-term survival of cell 
grafts after myocardial infarction 
with thick viable cardiac tissue 
entirely from pluripotent stem 
cells
Takehiko Matsuo1,2,3, Hidetoshi Masumoto1,2,3, Shuhei Tajima4, Takeshi Ikuno1,2,3, 
Shiori Katayama1,2, Kenji Minakata3, Tadashi Ikeda3, Kohei Yamamizu1,2, Yasuhiko Tabata4, 
Ryuzo Sakata3 & Jun K. Yamashita1,2
Poor engraftment of cells after transplantation to the heart is a common and unresolved problem 
in the cardiac cell therapies. We previously generated cardiovascular cell sheets entirely from 
pluripotent stem cells with cardiomyocytes, endothelial cells and vascular mural cells. Though 
sheet transplantation showed a better engraftment and improved cardiac function after myocardial 
infarction, stacking limitation (up to 3 sheets) by hypoxia hampered larger structure formation 
and long-term survival of the grafts. Here we report an efficient method to overcome the stacking 
limitation. Insertion of gelatin hydrogel microspheres (GHMs) between each cardiovascular cell sheet 
broke the viable limitation via appropriate spacing and fluid impregnation with GHMs. Fifteen sheets 
with GHMs (15-GHM construct; >1 mm thickness) were stacked within several hours and viable after 
1 week in vitro. Transplantation of 5-GHM constructs (≈2 × 106 of total cells) to a rat myocardial 
infarction model showed rapid and sustained functional improvements. The grafts were efficiently 
engrafted as multiple layered cardiovascular cells accompanied by functional capillary networks. 
Large engrafted cardiac tissues (0.8 mm thickness with 40 cell layers) successfully survived 3 months 
after TX. We developed an efficient method to generate thicker viable tissue structures and achieve 
long-term survival of the cell graft to the heart.
Recent progress in stem cell biology and tissue engineering are contributing to the development of var-
ious cell transplantation (TX) strategies. Nevertheless, a high and critical hurdle in tissue engineering is 
the size of viable cell mass through simple diffusion1–8. Furthermore, continuous beating of the heart and 
limitation in cardiomyocyte proliferation make it difficult to generate large and well survived cardiovas-
cular tissue structures in the heart by cell TX strategies. Thus, how to improve engraftment efficiency is 
a major challenge in cell TX strategies in the cardiac field9–13.
A cell sheet technology using a temperature-responsive culture surface coated by poly 
(N-isoproplyacrylamide) (PIPAAm)14,15 is an innovative method for the generation of 3D tissue. The 
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culture surface is hydrophobic at 37 °C, which makes it amenable for cells to attach on the dish, but 
becomes hydrophilic at room temperature, which allows cells to detach from the dish as a sheet-like 
structure. This cell sheet, which holds approximately 3-4 cell layers, can be directly applicable to cell 
TX16,17. However, in practice, 3 sheets (approximately 80 μ m thickness) is the upper limit for stacking 
due to hypoxic cell damage15,18.
We have been investigating cardiovascular cell differentiation and regeneration using pluripotent stem 
cells16,17,19–25. We have succeeded in systematically inducing various cardiovascular cells, i.e. cardiomy-
ocytes (CMs), endothelial cells (ECs), and vascular mural cells (MCs), from common progenitor Flk1+ 
cells19,23,24. Recently, we engineered cell sheets with defined cardiovascular cell populations entirely from 
mouse embryonic stem cells (ESCs) and human induced pluripotent stem cells (iPSCs), and transplanted 
3-sheet stacked constructs into a rat myocardial infarction model16,17. Though cardiac function was ame-
liorated after the sheet transplantation, the sheet survival after TX was limited to one month in the mouse 
ESC study16. Thus, new technology for the real regeneration of neo-cardiac tissue is needed.
Gelatin hydrogel is a biodegradable biomaterial that possesses excellent capacity as a cell culture sub-
strate. As the water content of gelatin hydrogel is more than 95%26, culture media and body fluids con-
taining oxygen and nutrients can be easily impregnated into gelatin hydrogel27–29. We recently reported 
that the addition of gelatin hydrogel microspheres (GHMs) into cell aggregates can improve cell survival 
in culture27. In the present study, we applied GHM technology to stack up cardiovascular cell sheets and 
succeeded in generating thick viable cardiac structures entirely from pluripotent stem cells. These struc-
tures were transplanted and formed organized and long-lasting cardiac tissue in vivo.
Methods
Reagents. Recombinant human vascular endothelial growth factor 165 amino-acid isoform (VEGF165) 
and 8-bromoadenosine-3′ ,5′ -cyclic monophosphate sodium salt (8bromo-cAMP) were purchased from 
R & D systems (Minneapolis, MN), and Nacalai Tesque (Kyoto, Japan), respectively. Gelatin for culture 
dish coating was purchased from Sigma-Aldrich (St. Louis, MO). Mitomycin-C was purchased from 
Kyowa Hakko Kirin (Tokyo, Japan). Cyclosporin-A was purchased from Wako Pure Industries, Ltd. 
(Osaka, Japan), and dissolved in dimethyl sulfoxide (DMSO) (Nacalai Tesque, Kyoto, Japan).
Antibodies. Monoclonal antibodies for murine vascular endothelial (VE)-cadherin (VECD1) 
and murine Flk1 (AVAS12) were prepared and labeled in our laboratory as described previously23,24. 
Phycoerythrin (PE)-conjugated CD31 was purchased from BD Biosciences-Pharmingen (San Diego, CA) 
and used for flow cytometry analysis. The following antibodies were used as first antibodies for immu-
nostaining: monoclonal antibodies for cardiac troponin-T (cTnT) (1:2000 for immunofluorescence [IF], 
1:500 for immunohistochemistry [IHC]; Thermo Scientific, Fremont, CA), CD31 (1:500 for IHC; BD 
Pharmingen), α -smooth muscle actin (α SMA) (1:200 for IF; Sigma-Aldrich), and polyclonal antibod-
ies for von Willebrand factor (vWF) (1:2000 for IF; DAKO, Carpinteria, CA), and HIF1 alpha (1:200 
for IF; GeneTex). The following antibodies conjugated with Alexa florescent dye were purchased from 
Invitrogen and used as second antibodies for immunostaining: anti-mouse IgG-Alexa546, anti-mouse 
IgG-Alexa594, anti-rat IgG-Alexa488, anti-rat IgG-Alexa546, and anti-rabbit IgG-Alexa488 (1:500 for 
IF). For cTnT-staining in cardiovascular cell sheets, sections were incubated for 60 minutes with primary 
antibody at room temperature, and then applied to EnVisionTM+ System-HRP (DAB) (DAKO) according 
to the manufacturer’s instructions. For CD31 staining, sections were applied to Histofine Simple Stain 
(Nichirei Biosciences Inc., Tokyo, Japan).
Mouse ESC culture. Two mouse ESC sublines from E14tg2a cell line were used as previously 
described16. Briefly, EMG7 mouse ESC line that carries the mouse α -myosin heavy chain (MHC) 
promoter-driven eGFP gene was used for the differentiation of CMs24,30. EStTA-ROSA mouse ESC line 
was used for the differentiation of ECs and MCs20.
Mouse ESC differentiation. Induction of and sorting for Flk1+ cells were performed based on 
our previous reports16,23,24. In summary, mouse ESCs were cultured in differentiation medium (DM) 
(alpha minimum essential medium [α MEM] [GIBCO, Grand Island, NY] supplemented with 10% fetal 
bovine serum [FBS] and 5.5 mmol/L 2-mercaptoethanol) without leukemia inhibitory factor (LIF) on 
gelatin-coated dishes for 96–112 hours. For the differentiation of CMs, purified Flk1+ cells were plated 
onto mitomycin-C-treated confluent OP9 cell sheets (MMC-OP9) and cultured in DM to induce CM 
differentiation. Cyclosporin-A (3 μ g/mL) was added to Flk1+ cell culture to promote CM differentia-
tion30. For the differentiation of ECs or MCs, purified Flk1+ cells were plated onto gelatin-coated dishes, 
and then cultured with DM in the presence of VEGF165 (50 ng/mL) and 8bromo-cAMP (0.5 mmol/L)31.
Flow cytometry analysis and cell sorting. After 4 days culture of Flk1+ cells on MMC-OP9, cul-
tured cells were harvested and subjected to cell sorting with FACS (fluorescence-activated cell sorting) 
(Aria III, BD Biosciences, Franklin Lakes, NJ). Viable GFP-positive cell population was evaluated and 
sorted as differentiated CMs (GFP+ CMs)19,24,30. ESC-derived ECs and MCs were selectively induced and 
harvested on the third day of Flk1+ cell culture on gelatin-coated dishes with VEGF and 8brom-cAMP 
(Flk-d3 EC/MC)21,31.
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Mouse ESC-derived cardiovascular cell sheet generation. Cell sheets with defined cardio-
vascular cell populations were generated as previously described16. In brief, Flk1+ cells induced from 
EStTA-ROSA cells were plated onto gelatin-coated 12- or 24-multiwell temperature-responsive culture 
dishes (UpCell) (CellSeed, Inc., Tokyo, Japan) at 37 °C in a humidified atmosphere containing 5% CO2. 
The cells were plated at 2.5–4.0 × 104 cells/well in a 12-multiwell UpCell or 1.4-2.2 × 104 cells/well in a 
24-multiwell UpCell with 1 mL of DM containing VEGF165 (50 ng/mL) and 8bromo-cAMP (0.5 mmol/L) 
to selectively induce ECs and MCs. After 3 days of EC and MC induction, separately prepared Flk-d3 
EC/MC (5.0 × 105 cells for 12 well, 2.2 × 105 cells for 24 well dish) and GFP+ CMs (5.0 × 105 cells for 
12 well, 2.2 × 105 cells for 24 well dish) were plated onto the UpCell dishes (i.e. purified C + E + M cells 
onto E + M underlying cells; C: CMs, E: ECs, M: MCs). After 4 days, the cultured cells were transferred 
to room temperature for 15–30 minutes to release the cultured cells as intact monolayer sheets.
Preparation of gelatin hydrogel microspheres. GHMs were prepared by dehydrothermal 
cross-linking of gelatin microspheres prepared in a water in oil emulsion state according to a method 
previously reported26,32. Briefly, an aqueous solution (20 mL) of 10 wt% gelatin (isoelectric point 5.0, 
weight-averaged molecular weight 100,000, Nitta Gelatin Inc., Osaka, Japan) was preheated at 40 °C, 
followed by stirring at 200 or 400 r.p.m. for 10 min to prepare water in oil emulsion. The emulsion 
temperature was decreased to 4 °C for natural gelation of the gelatin solution to obtain non-crosslinked 
microspheres. The resulting microspheres were washed three times with cold acetone in combination 
with centrifugation (5000 r.p.m., 4 °C, 5 min) to completely exclude residual oil. Then they were fraction-
ated by size using sieves with apertures of 20, 32, and 53 μ m (Iida Seisakusho Ltd, Osaka, Japan) and air 
dried at 4 °C. The non-crosslinked and dried gelatin microspheres (200 mg) were treated in a vacuum 
oven at 140 °C and 0.1 Torr for dehydrothermal crosslinking of gelatin according to a previously reported 
method26,32.
Stacking cell sheets. Spontaneously detached cell sheets were suspended in aqueous media. To stack 
the cell sheets, one cell sheet with culture media was gently aspirated into the tip of a 5 or 10 mL-pipette 
and transferred onto a new gelatin-coated 60 mm or 35 mm culture dish. After spreading the cell sheet 
without folds by aspirating the medium, PBS with GHMs (100 μ g/μ L) or PBS alone was put and spread 
on the surface of the cell sheet (5 μ L and 2.5 μ L for 12-multiwell and 24-multiwell UpCell-derived sheets, 
respectively). The dishes were incubated at 37 °C for 30 min to allow the cell sheet to adhere to the 
culture surface. Then a second cell sheet was placed on top of the first and attached without folds by 
aspirating the media. In a similar way, quintuple-stacked constructs (5-constructs) were generated on the 
culture dishes (Fig. 1). Before TX, the constructs were pre-stained with Hoechst 33342 (Life Technologies 
Carlsbad, CA) for 30 minutes and washed with DM. The constructs were detached from the culture dish 
by flushing several times with culture medium using a 1000 μ L micropipette. To obtain 10-constructs, 
Figure 1. Cardiovascular cell sheet stacking with GHMs in vitro. Process of cardiovascular cell sheet 
stacking. The first cardiovascular cell sheet is put into a dish with medium. The sheet is spread out on the 
dish during medium aspiration. GHM-containing solution is added drop-wise and spread on the surface, 
and then incubated at 37 °C in the absence of medium for 30 minutes. A second cardiovascular cell sheet is 
then applied on the first sheet with medium. The same procedure is repeated until 5 layers are stacked.
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a second 5-construct was overlaid on the first one, and to obtain 15-constructs, a third 5-construct was 
overlaid on the 10-construct.
Live/Dead assay. A layered cardiovascular cell sheet was used to evaluate cell viability. Seven days 
after cultivation, the constructs were incubated with staining solution (50 mL/L Ethidium Homodimer 
III and 50 mL/L Hoechst 33342, PromoCell GmbH, Heidelberg, Germany) in a pH-adjusted buffer for 
15 minutes at room temperature and protected from light. Fluorescent images were obtained using a 
microscope (Biorevo BZ-9000, Keyence, Osaka, Japan).
TUNEL assay. Seven days after stacking cardiovascular cell sheets, apoptosis was assessed in cross 
sections with TUNEL assay (Click-iT Plus TUNEL Assay, Invitrogen) following the manufacturer’s 
instruction. Briefly, the cardiovascular sheets were fixed in 4% paraformaldehyde and routinely pro-
cessed into 5-μ m-thick paraffin-embedded sections. These samples were deparaffinezed and fixed in 4% 
paraformaldehyde again. Then EdUTP nucleotide was incorporated into dsDNA strand breaks by TdT 
enzyme and attached an Alexa Fluor picolyl azide dye. Fluorescent images were obtained using a micro-
scope (Biorevo BZ-9000, Keyence). The numbers of TUNEL-positive cells and DAPI was calculated by 
Image-J software.
Animals. All animals including NOD-SCID mice (10 weeks old, male) and F344/NJcl-rnu/rnu rats 
(athymic nude rats; 8-10 weeks old, male) were purchased from CLEA Japan (Osaka, Japan). All animal 
experimental protocols were approved by the Animal Experimentation Committee, Kyoto University. 
All animal experiments were performed according to the ‘Guidelines for Animal Experiments of Kyoto 
University’, which confirms to Japanese law and ‘the Guide for the Care and Use of Laboratory Animals’.
Myocardial infarction. Male athymic nude rats aged between 10–12 weeks were housed in a con-
trolled environment. Myocardial infarction (MI) was induced in isoflurane-anaesthetized rats by per-
manent ligation of the left anterior descending coronary artery as previously described16,33,34. Rats of 
which hearts showed more than 30% left ventricular (LV) fractional shortening (FS) in echocardiograms 
6 days after ligation were excluded from subsequent experiments. Hearts were harvested at 1 to 12 
weeks after treatment/sham operation and prepared for immunofluorescence, immunohistochemistry 
and species-specific fluorescent in-situ hybridization (SS-FISH).
GHM-constructs transplantation. Seven days after inducing MI, each rat was randomly assigned 
to one of the three groups: GHM-construct TX group, control-construct TX group, and sham group. In 
the former two groups, five-cardiovascular cell sheet constructs with or without GHMs were applied to 
the surface of the anterior wall of the heart as previously described16. In summary, the constructs were 
spread manually to cover the whole MI area and the border area and stably placed onto the surface of 
the heart without sutures. The chest was closed 15–20 minutes after surgery. In sham-operated group, the 
chest was closed 15–20 minutes after thoracotomy.
Cardiac function assessment. To assess global cardiac function and left ventricle (LV) size, echo-
cardiograms were performed with the Vivid 7 system (GE Healthcare, Waukesha, WI) and an 11-MHz 
imaging transducer (GE 10S ultrasound probe, GE Healthcare). Echocardiograms were performed before 
ligation (baseline), and on day 6 (pre TX, i.e., 6 days post-MI), and 1, 2, 4, 8, and 12 weeks after TX by 
an independent person in a blinded fashion as previously described16,33,34. Diastolic and systolic area of 
LV (LVAd, LVAs), diastolic lengths of LV inner circumference (CIRCd) and those of akinetic area in dias-
tole (SCAR) were recorded and measured with B-mode examination. Values were calculated as follows:
Fractional shortening (FS) (%) = (LVDd–LVDs)/LVDd × 100.
Akinetic length (AL) (%) = SCAR/CIRCd × 100.
Besides the experimental model (GHM-construct TX group, control TX group, or sham group), echo-
cardiograms were performed on normal rats, which had no surgical intervention in order to quantify the 
normal values of the parameters of the lineage/age/weight-matched rats (n = 5).
Species-specific FISH analysis. FISH probes which recognize and hybridize with sequence repeats 
specific for each animal species were arranged by Chromosome Science Labo (Sapporo, Japan)16,35,36. 
The nucleotide probes were applied to the fixed and pre-treated sections that were denatured and then 
hybridized. Additional IF staining for cTnT and vWF was performed on the FISH samples. Samples were 
examined by fluorescence microscopy (LSM 710 Laser Scanning Microscopes, Carl Zeiss, Oberkochen, 
Germany) and Carl Zeiss software.
Histological analyses. For cross-sectional observation, cardiovascular cell sheets were fixed in 4% 
paraformaldehyde and routinely processed into 5-μ m-thick paraffin-embedded sections. Hematoxylin 
and eosin (HE) staining was performed using conventional methods as previously described16,33,34. For 
cTnT-staining, sections were incubated for 60 min with primary antibody at room temperature, and 
then applied to LSAB2 kit/horseradish peroxidase (HRP) (diaminobenzidine; DAB) (DAKO) accord-
ing to the manufacturer’s instructions. Hearts were immersed and perfusion fixed with 4% PFA and 
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embedded in OCT compound (Sakura Finetek Japan, Tokyo, Japan) and frozen. Several 5-micrometer 
sections were made at 50-μ m intervals along the short axis and examined. For IF staining, sections were 
treated with Protein Block Serum Free (DAKO) and incubated for 60 min with primary antibodies at 
room temperature. The area of engraftment was calculated as double positive cells for cTnT staining 
and mouse signal with SS-FISH or as positive cells for Hoechst 33342. For lectin perfusion analysis, rats 
were received intravenous injections of 1.5 ml of 1 mg/ml DyLight 594-conjugated tomato (Lycopersicon 
esculentum) lectin (Dye-lectin) (Vector Labs, Burlingame, CA) in PBS into the inferior vena cava 15 
min prior to sacrifice. After excision, the hearts were sectioned manually into 5-micrometer that were 
made at 50-micrometer intervals along the short axis and examined. All immunostained sections were 
photographed and calculated with Biorevo BZ-9000 or LSM 710 Laser Scanning Microscopes (Carl Zeiss, 
Oberkochen, Germany).
Extracellular field potential measurement. Extracellular field potential (EFP) of cell sheet con-
structs before and after TX was measured by the difference between electric potentials of two sensor 
electrodes with 1 mm distance (Research electrode SCR-2; unique medical co). The electric potential was 
amplified (bio-signal amplifier unit; unique medical co) and recorded (UAS-3088; unique medical co). 
Just before TX of 5-GHM constructs, EFP was measured by direct attachment of the sensor electrodes 
to the cell sheet constructs in a medium (sheet EFP (in vitro)). Then, the constructs were transplanted 
to the normal hearts of male athymic nude rats (F344/N Jcl-rnu/rnu, CLEA Japan, Inc., Tokyo, Japan) 
aged 12 weeks. EFP of the transplanted cell constructs was measured by direct attachment of the elec-
trodes on the surface of the cell constructs (sheet EFP (heart)) with simultaneous recording of the rat 
electrocardiogram (ECG).
Statistical analysis. Results are presented as mean ± s.e.m. P values were obtained with 
non-parametric statistics; Mann-Whitney U test for a non-parametric test using GraphPad Prism 5 for 
Windows (version 5.03, GraphPad Software, Inc., San Diego, CL). Comparisons between > 2 groups were 
performed using a Kruskal-Wallis one-way analysis of variance by ranks for a non-parametric test, then 
by post-hoc comparisons between groups by Steel-Dwass test. Differences were considered statistically 
significant when P < 0.05.
All experimental protocols including animal and recombinant DNA experiments were approved by the 
Animal Experimentation Committee and Agency of Health, Safety, and Environment, Kyoto University.
Results
Stacking of pluripotent stem cell-derived cardiovascular cell sheets with GHM insertion. We 
prepared pure cardiovascular cell populations, i.e. CMs, ECs and MCs, from Flk1+ cardiovascular pro-
genitor cells in our mouse ESC differentiation system, and generated cardiovascular cell sheets by 
re-assembling them as previously reported16. These sheets consisted of CMs (45.6 ± 3.8% of total cells), 
ECs (9.9 ± 1.7%), and MCs (41.8 ± 3.3%) (n = 14, FACS-analyzed) (Supplementary Fig. S1). Total cell 
count of each sheet (generated in 12-well UpCell dishes) was 3.73 ± 2.7 × 105 on average (n = 14). We 
then manually stacked the cell sheets one by one with the insertion of GHMs by adding drop-wise 
and spreading the GHM solution onto the entire surface of the sheet (Fig. 1). We optimized doses and 
sphere sizes of GHMs (Supplementary Fig. S2). Insertion of approximately 0.5 mg/cm2 of GHMs (ϕ 
20–32 μ m) achieved highly viable stacked cell sheets even after 1 week of culture (Fig. 2A,B). Cell con-
structs of 5-sheets with GHMs (5-GHM constructs) showed dramatically thicker wall (597.1 ± 23.95 vs. 
250.9  ±  17.7 μ m, n = 5, **P < 0.01, *P < 0.05; Fig. 2C) and greater viable cell area (0.4648  ±  0.03102 
vs. 0.03511  ±  0.009244 mm2, n = 5, *P < 0.05; Fig. 2D) than 5-sheet constructs simply stacked without 
GHMs (5-control constructs). Immunostaining for cTnT and CD31 demonstrated that CM and EC con-
tents were increased approximately 13.6-times and 5.2-times with GHM insertion than control, respec-
tively (Fig. 2E–G). Thus, GHM insertion efficiently helps to stack cardiovascular cell sheets.
Mechanisms and roles of GHM insertion. We next examined the mechanisms and roles of GHMs 
in the efficient cell sheet stacking. First we evaluated cell survival with Live/Dead assay. Whereas half of 
the cells became necrotic after 1-week culture of control constructs, almost all cells were alive in 5-GHM 
constructs (Fig. 3A–C). TUNEL assay also demonstrated efficient reduction of apoptosis in 5-GHM con-
structs in vitro (Fig. 3D–E). Whereas approximately 45% of nuclei were positive for TUNEL after 1-week 
culture in control constructs, GHM insertion significantly reduced TUNEL-positive nuclei to approxi-
mately 15% of total nuclei, indicating that GHMs dramatically reduced apoptosis after cell sheet stacking. 
We further examined hypoxic status in the cultured cell sheets with hypoxia-inducible factor 1α (HIF1α) 
expression (Fig.  3F). Although HIF1α was broadly expressed in stacked cell layers in the control after 
1-week culture, the expression was largely reduced in 5-GHM constructs, suggesting that hypoxic status 
in the stacked cell sheets can be reduced with GHM insertion. Higher magnification view of 5-GHM 
constructs (Fig. 3G) showed scattered insertion of GHMs between each cardiovascular cell sheet (arrow-
heads in Fig.  3G). GHMs should provide appropriate spaces between cell sheets and be impregnated 
with culture media, which should allow oxygen and nutrients to reach each cell sheet broadly. In addi-
tion, GHMs did not block the direct contact between each sheet (circles in Fig. 3G), which resulted in 
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synchronous beating of whole cell constructs. We confirmed electrical coupling between the stacked cell 
sheets by directly measuring EFP of the stacked cell sheet constructs (sheet-EFP). 5-GHM constructs in a 
culture dish showed spontaneous contraction with a single synchronous sheet-EFP wave (Supplementary 
Fig. S3a, d). Thus, all these data suggest that GHM insertion can endow ideal features as cardiac tissue, 
thick viable structure and electrical coupling, on the stacked cardiovascular cell sheet constructs.
Figure 2. Characteristics of cardiovascular cell sheet constructs. (A,B) Cross-sections of stacked sheets 
with or without 0.5 mg/cm2 of GHMs (ϕ 20–32 μ m) inserted between. HE staining after 7-day culture. Scale 
bars, 50 μ m. Magnifications, x200. (A) 5-Control: 5-sheet constructs without GHMs. (B) 5-GHM: 5-sheets 
with GHMs. (C,D) Thickness of constructs and viable cell area (HE-positive area) after 7-day culture. 
Mean ± s.e.m. **P < 0.01, *P < 0.05 (Mann-Whitney U-test, n = 5). (E,F) Immunostaining for cTnT (brown) 
after 7-day culture. 5-control (E) and 5-GHM (F) constructs. Scale bars, 50 μ m. Magnifications, x200. 
(G) Quantitative evaluation of cTnT-positive and CD31-positive area. Mean ± s.e.m. **P < 0.01 (Mann-
Whitney U test, cTnT, n = 9; CD31, n = 6).
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Efficient generation of thick viable cardiac cell structures with GHM method. This simple and 
easy procedure of the GHM method is amenable to generate much thicker sheet constructs. We prepared 
a number of 5-GHM constructs and then stacked them to generate 10- or 15-GHM constructs within 
several hours. After 1-week culture of 10- or 15-GHM constructs, viable thicker cardiovascular cell sheet 
constructs were successfully generated (Fig.  4). The thickness reached more than 1 mm on average in 
15-GHM constructs (10-GHM, 911 ± 19.8 μ m; 15-GHM, 1050 ± 16.2 μ m; n = 4). The thickness of cel-
lular components (HE-positive area/sheet length) in 10-GHM and 15-GHM constructs was calculated 
to 529 ± 55.5 μ m and 670 ± 22.3 μ m on average (n = 4), respectively (Fig.  4A,B). Immunostaining for 
cTnT (CMs) and vWF (ECs) clearly demonstrated that the constructs consisted of multi-layered, viable 
CMs with vascular cells (Fig. 4C). Thus, all-pluripotent stem cell-derived, thick viable cardiovascular cell 
Figure 3. Mechanisms and roles of GHM insertion. (A,B) Live/Dead assay after 7-day culture. Live cells 
(blue), necrotic cells (red). (C) Areas in cross sections. **P < 0.01, *P < 0.05 (Mann-Whitney U test, n = 4). 
Scale bars, 50 μ m. (D,E) TUNEL assay. (D) TUNEL staining in cross sections after 7-day culture. TUNEL 
(green), DAPI (blue). Scale bars, 100 μ m. (E) Percentage of TUNEL-positive cells in total cells (DAPI). 
**P < 0.01 (Mann-Whitney U test, 5-control, n = 4; 5-GHM, n = 3). (F) HIF1α immunostaining after 
7-day culture. HIF1α (green), DAPI (blue). Scale bars, 50 μ m. (G) A higher magnification view of Fig. 2B. 
Arrowheads indicate GHMs. Open circles indicate direct contacts between one cardiovascular sheet and the 
other. Scale bar, 30 μ m. All photos are taken with x200 magnification.
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constructs consisted of multi-layered CMs and vascular cells can be successfully generated in vitro by the 
cell sheet stacking with GHM insertion method.
Functional improvements of infarcted hearts after GHM-construct TX. Next we transplanted 
the constructs in vivo. First we confirmed the survival of the constructs by TX to the subcutaneous 
spaces of NOD/SCID mice. The constructs were pre-stained with Hoechst 33342 just before TX. Seven 
days after TX, whereas almost no transplanted cells survived in 5-control construct TX, distinct tissue 
structures were still preserved in 5-GHM construct TX under the skin (Supplementary Fig. S4). Next we 
transplanted the constructs (generated in 12-well UpCell dishes) to a myocardial infarction (MI) model. 
Seven days after the ligation of the left coronary artery (sub-acute MI model), Hoechst-pre-stained con-
structs were transplanted to cover the infarcted area (Supplementary Fig. S5). We evaluated effects of 
GHM construct TX on the infarcted hearts by assessing global cardiac function and left ventricle (LV) 
size with echocardiogram (Table  1). Whereas in the sham-operation group, infarcted wall motion was 
reduced and cardiac function (FS; fractional shortening) did not change and showed a tendency to fur-
ther deteriorate until 12 weeks after treatment, 5-control construct TX showed weak beneficial effects 
on cardiac function (FS) and akinetic length (AL) (Fig.  5A,B, Table  1). 5-GHM construct TX exerted 
much rapider and greater effects, including significant recovery of FS from 1 week after TX and further 
improvement towards 12 weeks after treatment. AL also significantly decreased to almost undetectable 
levels within 4 weeks. 5-GHM construct TX significantly improved FS than sham and control groups 
at 4 weeks after TX (Fig.  5C, Table  1). Enlargement of systolic diameter of left ventricle (LVDs) was 
significantly reduced with 5-GHM construct TX than sham group. Diastolic diameter (LVDd) dilatation 
showed a tendency to be reduced in 5-GHM group (Table 1). Thus, the GHM insertion brought benefi-
cial outcomes in the rapid and long-term functional rescue of infarcted hearts after sheet TX.
Survival, maturation, and re-organization of GHM-constructs in infarcted hearts. Next, 
we examined the engraftment status of the sheet constructs. Our previous results16 as well as others37 
Figure 4. Efficient generation of thick viable cardiac cell structures with GHM method. Thick GHM 
constructs with 10–15 cardiovascular cell sheets in vitro after 7-day culture. (A,B) HE staining. Note that 
construct thickness reaches more than 1 mm in 15-GHM. (C) cTnT (CMs; red), vWF (ECs; green) and 
DAPI (blue) staining. cTnT-negative/vWF-negative/DAPI-positive cells can be estimated as MCs. Inset: 
clear viable CM layers (red) include ECs (green). Scale bars, 100 μ m. All photos are taken with x100 
magnification.
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indicated that pluripotent stem cell-derived sheets almost disappear within one or two months after TX 
to infarcted hearts. In this study, a larger engraftment (Hoechst-positive cells) with 5-GHM constructs 
was observed from 1 week after TX (Fig. 6A) and was sustained until 12 weeks after TX. The estimated 
engrafted areas at 1 week or 4 weeks after TX were approximately 5 times more than those of 5-control 
constructs (1 week, 4.44 ± 0.78, n = 7 vs. 1.06 ± 0.65 mm2, n = 4, P < 0.05; 4 weeks, 3.10 ± 0.47, n = 5 
vs. 0.67 ± 0.15 mm2, n = 4, P < 0.01, Fig.  6B). Whereas survived area was reduced to an undetectable 
level in the 5-control construct group until 12 weeks after the TX, a substantial amount of graft was 
maintained in the 5-GHM construct group (12 weeks, 2.48 ± 0.19 vs. 0.11 ± 0.0054 mm2, n = 4, P < 0.01, 
Fig.  6B). Decrease rate in survived graft area was decelerated after 4 weeks to 12 weeks of TX, sug-
gesting further long-term survival of the graft could be expected. Staining for cardiovascular cell types 
demonstrated tissue remodeling occurred after the construct TX. Neovascularization mainly with host 
ECs was induced in close proximity to the grafts compatible with our previous 3-control sheet TX16 
(Supplementary Fig. S6). In addition, blood vessel formation was also observed in the survived grafts. 
ECs had accumulated at 1 week and formed clear lumen structures in the grafts at 4 weeks after TX, 
respectively (Fig.  6C). The majority of non-CM/non-EC cells in the grafts were α SMA-positive mural 
cell population (Supplementary Fig. S7). Many CMs survived and formed layers of neo-CMs that started 
to show sarcomere formation though it was still immature (4 weeks, Fig.  6D). We further confirmed 
connection with the systemic circulation by venous infusion of Dye-lectin that marked perfused ves-
sels (Fig.  6E–G). Surprisingly, drastic re-organization of the grafts was observed at 4 weeks after TX. 
Various sizes of functional vessels, such as blood vessels with clear lumen and smaller capillaries, were 
formed in the grafts. The majority of these functional vessels were generated from Hoechst-positive 
graft-derived ECs (Fig.  6E, I and II). Massive neo-CMs survived and formed large layered structures 
(> 20 layers), which were completely supported by the dense capillary network. Even in 12 weeks after 
TX, the vascular-supported grafts efficiently survived and formed a large cardiac structure (> 0.8 mm 
thickness, 40 cell layers, in maximum) (Fig. 6F). GHMs that are used in this study was estimated to be 
degradated in vivo around 3 weeks in previous studies38. No GHMs were detectable in 12 weeks after 
TX and instead the grafts were occupied with cellular or tissue components. Compact CM tissue with 
functional capillary vessels was successfully formed (Fig.  6G). These results indicate that transplanted 
grafts from pluripotent stem cells were successfully integrated into the heart with blood supply and 
re-organized into solid neo-CM tissues during the long-term survival.
We finally examined electrical coupling between the graft and host heart after TX. We recorded 
sheet-EFP and rat electrocardiogram (ECG) simultaneously (Supplementary Fig. S3). 5-GHM constructs 
before TX showed spontaneous beating with a distinct rhythm from the rat heart beat recorded by ECG 
(Supplementary Fig. S3a, d). After TX to normal rat heart (Supplementary Fig. S3b), sheet-EFP showed 
only synchronized rhythm with the rat ECG (Supplementary Fig. S3e), suggesting that the electrical 
coupling between the graft and host should be established. No increase in sudden death was observed 
after TX (data not shown), suggesting that lethal arrhythmia should not be induced by TX. Though 
it is difficult to directly assess actual mechanical support that the graft generated, transplanted GHM 
constructs may contribute to functional improvement after MI through both paracrine effects and direct 
contraction.
Group baseline pre Tx 1w 2w 4w 8w 12w
LVDd (mm)
Sham 6.4  ±  0.1 7.3 ± 0.2 7.3 ± 0.3 7.8 ± 0.4 8.2 ± 0.5 8.1 ± 0.3 9.2 ± 0.4
5-Control 6.3 ± 0.2 7.5 ± 0.2 8.2 ± 0.1 8.0 ± 0.1 8.2 ± 0.1 8.9 ± 0.2 9.3 ± 0.3
5-GHM 6.2 ± 0.1 7.3 ± 0.2 7.6 ± 0.2 7.9 ± 0.2 8.1 ± 0.2 7.4 ± 0.7 8.2 ± 0.4
LVDs (mm)
Sham 3.0 ± 0.1 5.6 ± 0.2 5.8 ± 0.3 6.2 ± 0.3 6.6 ± 0.5 6.6 ± 0.3 7.5 ± 0.4
5-Control 3.0 ± 0.2 5.8 ± 0.2 6.1 ± 0.2 5.6 ± 0.3 6.2 ± 0.2 6.3 ± 0.2 6.4 ± 0.2
5-GHM 2.7 ± 0.1 5.5 ± 0.2 5.0 ±  ± 0.2*†† 5.1 ± 0.3 5.1 ± 0.3*† 4.1 ± 0.6** 4.5 ± 0.2**
FS (%)
Sham 53.9 ± 1.3 23.1 ± 1.4 20.7 ± 1.0 20.4 ± 1.2 19.1 ± 1.6 18.8 ± 1.3 18.7 ± 1.2
5-Control 52.3 ± 1.7 23.1 ± 1.6 26.1 ± 1.3* 29.8 ± 2.9* 25.3 ± 1.7 29.5 ± 2.2* 32.1 ± 0.9*
5-GHM 56.6 ± 1.5 24.9 ± 0.7 34.9 ± 1.5**†† 36.3 ± 2.1*** 37.3 ± 2.7***†† 45.4 ± 3.9** 44.8 ± 1.7**
Akinetic length (%)
Sham 0.0 24.5 ± 3.3 29.3 ± 2.8 26.0 ± 2.0 28.2 ± 3.6 34.2 ± 5.2 29.2 ± 3.0
5-Control 0.0 23.1 ± 3.1 14.9 ± 2.8* 13.3 ± 3.0* 16.6 ± 3.2 17.7 ± 1.6 19.1 ± 0.7
5-GHM 0.0 22.6 ± 1.7 5.5 ± 1.7***† 5.4 ± 1.5*** 0.5 ± 0.4***†† 0.0***† 0.0**†
Table 1.  Echocardiogram after 5-cell sheet construct TX to rat myocardial infarction model. *p < 0.05, 
**p < 0.01 vs Sham, †p < 0.05, ††p < 0.01 vs 5-Control. Kruskal-Wallis test, post-hoc Steel-Dwass multiple 
comparison test, sham, n = 6; 5-control, n = 11; 5-GHM, n = 10.
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Discussion
Combining novel technologies in stem cell biology and tissue engineering, we succeeded in generat-
ing vascularized and organized large cardiac tissue from pluripotent stem cells that efficiently survived 
long-term in infarcted hearts.
Because CMs principally do not proliferate and the heart is continuously beating, cell TX and effi-
cient graft survival in the heart are much more difficult than other cell types or tissues9,10,39. Recently, a 
mixture of human iPS cell-derived hepatocytes with human umbilical vein ECs and mesenchymal cells 
was reported to generate 3D tissue structure in vitro and in vivo40. In this case, the cell aggregates could 
survive and grow on a cranial mesentery, a stable environment. As for cardiac cells, TX of cardiovascular 
cell sheets to subcutaneous tissue, also a stable environment, showed a long-term survival41. In another 
recent article, needle-injected human ESC-derived CMs were reported to successfully survive and be 
engrafted in monkey hearts. The thickness of the grafted CMs reached approximately 2 mm in a cross 
section sample42, which is more than two times thicker than our maximum graft thickness after 5-GHM 
construct TX (approx. 0.8 mm). However, the total transplanted cell number is more than 500 times less 
in our model than that report (approx. 1.9 × 106 cardiovascular cells vs 109 human CMs). Though it is 
Figure 5. TX of cardiovascular cell sheet constructs to rat infarcted hearts. (A) Representative M-mode 
echocardiographic images at baseline (before MI), pre TX, and 1, 4, and 12 weeks after TX. Yellow dashed 
lines indicate anterior wall movements. (B) FS and AL measured by echocardiogram. Mean ± s.e.m. 
***P < 0.001, **P < 0.01, *P < 0.05 versus sham-treated group, ††P < 0.01, †P < 0.05 versus 5-Control group 
(Kruskal-Wallis test, post-hoc Steel-Dwass multiple comparison test, sham, n = 6; 5-control, n = 11; 5-GHM, 
n = 10). (C) Changes in FS (Δ FS) between pre-TX and 4 weeks. *P < 0.05 versus sham-treated group, 
†P < 0.05 versus 5-Control group (Kruskal-Wallis test, post-hoc Steel-Dwass multiple comparison test, sham, 
n = 6; 5-control, n = 11; 5-GHM, n = 10).
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Figure 6. Engraftment status of sheet constructs. (A) Nuclei staining images (blue) for pre-stained 
Hoechst (grafts, left) and DAPI (total cells, right). White dashed lines indicate graft areas. Magnifications, 
x40. (B) Quantitative evaluation of engrafted areas. Mean ± s.e.m. **P < 0.01, *P < 0.05 (Mann-Whitney U 
test, 1 week: 5-Control, n = 4; 5-GHM, n = 7; 4 weeks: 5-Control, n = 4; 5-GHM, n = 5; 12 weeks: 5-Control; 
n = 4, 5-GHM; n = 4). (C) Immunofluorescence staining for cTnT (red) and vWF (green) of heart sections 1 
(left) and 4 (right) weeks after TX of 5-GHMs. Lower panels: high-magnification images (x400) of white boxes 
in upper panels (x100). White arrowheads: blood vessel formation with vWF-positive cells. Clear vascular-
like structures were formed at 4 weeks. (D) High-magnification image (x1000) of yellow box in (C). Inset: 
immature sarcomere formation in white box in (D). (E,F) Connection of grafts with systemic circulation. 
CMs (cTnT, red), perfused vessels (lectin-stained, green), pre-stained graft nuclei (Hoechst, blue). (E) Four 
weeks after TX. Note that thick neo-CM layers (> 20 layers; white double-headed arrow) supported by dense 
perfused capillary networks (green) were formed. Magnification, x200. Capillaries (I) and larger vessels (II) 
in the graft (green) were largely Hoechst-positive. Magnification, x1000. (F) Twelve weeks after TX. A Large 
graft (> 0.8 mm thickness, > 40 cardiac cell layers, in maximum) survived. Magnification, x200. (G) High-
magnification image (x400) of white box in (F). A compact CM tissue with capillary vessels was formed. Scale 
bars, 300 μ m (A), 100 μ m (C, upper and F), 50 μ m (E,G), 30 μ m (C, lower), and 10 μ m (D, E-I and II).
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difficult to directly compare the efficiencies of the engraftments between the two studies because the 
cell species and TX methods are different, our method has the potential to generate vascularized and 
long-term surviving thick cardiac tissue in the hearts from a relatively small numbers of transplanted 
cells.
Additionally, significant and sustained cardiac functional recovery after TX was observed in 
our study, suggesting a potential for the application of the strategy to cardiac regenerative therapy. 
Of course, whether our strategy can be extended to larger animals using human pluripotent stem 
cells requires further study. Based on our human induced pluripotent stem cell (iPSC) differentia-
tion method to CMs25,43, we recently developed a new and efficient cardiovascular cell differentiation 
method from human iPSCs, in which cardiovascular populations (CMs, ECs, and MCs) are simulta-
neously induced as a cell mixture. We generated 3-stacked human iPSC-derived cardiovascular cell 
sheets and confirmed functional improvements after TX to a rat myocardial infarction model17. In 
that study, we observed some cases in which relatively larger grafts survived 1-2 months after TX, 
suggesting that human iPSC-derived cardiovascular cell sheets may possess higher survival features 
than mouse ESC-derived sheets. We have applied GHMs to human iPSC-derived sheets and already 
succeeded in generating 5-stacked thicker cardiac cell structures (Supplementary Fig. S8). Clinical rel-
evance of GHM-sheet stacking strategy should be examined with human iPSC-derived cardiovascular 
cell sheets using larger animal models. Usefulness of the strategy including mechanisms of functional 
improvement, i.e. paracrine effects and/or mechanical supports, maturation of CMs in the grafts, and 
safety issues such as arrhythmogenicity and tumorigenicity should be further addressed before moving 
to the clinical stage.
In our method, cellular components, CMs, ECs, and MCs, are entirely derived from pluripotent 
stem cells. Recently, generation of 3D cardiac structures with blood vessels was reported using rat 
primary CM and EC culture cells18,44,45. In those reports, cardiac cell sheets with primary cultured 
cells were layered on bioreactors that can perfuse the cell sheet culture. However, 3-layer cell sheets 
were stacked sequentially at 1-week intervals, thus requiring around 20 days to generate a 12-sheet 
structure with approximately 100 μ m thickness in vitro and 1 mm in vivo18,44,45. Our easy and efficient 
method can generates large viable 3D cardiac structures all from pluripotent stem cells within several 
hours in a manner suitable for the industrialization of stem cell medicine assuming large-scale and 
stable cell preparation.
Additionally, our method is highly expandable in terms of cell types and GHM functions. Recent stud-
ies revealed importance of vascular cells and mesenchymal cells in 3D tissue formation40,46. Combination 
of our method with other parenchymal cells (hepatocytes, renal epithelial cells and so on) should con-
tribute to the generation of various stem cell-derived large 3D tissues/organs both in vitro and in vivo. 
Moreover, GHMs can be modified to have additional functions, such as controlled release of growth 
factors and small molecules27,47,48. Slow release of angiogenic and/or survival factors should enhance the 
construct function after TX and integration process to the tissues.
Thus, our method is an important step in the generation of long-lasting cardiac tissue with cell TX 
and should contribute not only to cardiac cell therapy but also broadly to 3D tissue engineering and 
regenerative medicine.
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